After Glenmark, Dr Reddy’s Launches Favipiravir For Indian Market
Pfizer, Novartis and Mylan Announce Further Measures To Tackle The Pandemic
While Dr Reddy’s partners with Fujifilm Toyama for favipiravir for the Indian market, Pfizer and Gilead join together to increase the manufacturing and supply of investigational antiviral treatment remdesivir. Mylan donates a million dollars to Sesame Workshop to provide socio-emotional support to children and families to cope with the uncertainties caused by COVID-19, while Glenmark introduces a higher strength of Fabiflu for the Indian market.
You may also be interested in...
As Sandoz tries to assist African Union member states by selling its pandemic response portfolio medicines for zero profit, mAbxience has partnered with AstraZeneca to produce a vaccine. And CDMO Hovione has struck a deal with Ligand to boost manufacturing of Captisol, a critical ingredient for Gilead’s remdesivir.
India’s Saptagir Laboratories has struck a deal with Jubilant Pharma to manufacture the ingredient for COVID-19 emergency treatment remdesivir. Meanwhile, following in the footsteps of Cipla, Hetero, Mylan and Zydus, Dr Reddy’s has launched its version of remdesivir for the Indian market under a licensing deal with Gilead.
Hikma has seen its reported operating profit jump by a quarter in the first half of 2020, as a lift from its injectables business helped to drive up turnover by almost a tenth.